Pharmacological characterisation of CR6086, a potent prostaglandin E2 receptor 4 antagonist, as a new potential disease-modifying anti-rheumatic drug

Pharmacological characterisation of CR6086, a potent prostaglandin E2 receptor 4 antagonist, as a new potential disease-modifying anti-rheumatic drug

Abstract Background Prostaglandin E2 (PGE2) acts via its EP4 receptor as a cytokine amplifier (e.g., interleukin [IL]-6) and induces the differentiation and expansion of inflammatory T-helper (Th) lymphocytes. These mechanisms play a key role in the onset and progression of rheumatoid arthritis (RA)...

Full description

Bibliographic Details
Main Authors: Gianfranco Caselli, Albino Bonazzi, Marco Lanza, Flora Ferrari, Daniele Maggioni, Cristian Ferioli, Roberto Giambelli, Eleonora Comi, Silvia Zerbi, Marco Perrella, Ornella Letari, Elena Di Luccio, Milena Colovic, Stefano Persiani, Tiziano Zanelli, Laura Mennuni, Tiziana Piepoli, Lucio Claudio Rovati
Format: Article
Language:English
Published: BMC 2018-03-01
Series:Arthritis Research & Therapy
Subjects:
Arthritis
EP4 receptor antagonist
CR6086
Immunomodulatory potential
Collagen-induced arthritis
Online Access:http://link.springer.com/article/10.1186/s13075-018-1537-8

Internet

http://link.springer.com/article/10.1186/s13075-018-1537-8

Similar Items